Panel Discussion on ‘Next growth frontiers for India Pharma Inc’

Panelists in this video:
+ Mr Sunil Durge, Site Operation Head – API, Amneal Pharmaceuticals (Moderator)
+ Mr Satyashodhan Patil, Dy GM (R&D) – Device Development (Global Market), Sun Pharma
+ Mr Mayur Patel, Head-Formulation Development, Apnar Pharma
+ Dr Tarang Shah, Head – Bioequivalence & Pharmacovigilance, Alembic Pharmaceuticals
+ Mr Nagesh Nanda, Director, Novel Consultants

Key Highlights:
[1] Digital pills can disrupt the pharma and healthcare industries. It can bring better patient adherence and health outcomes, especially for patients with critical conditions and mental disorders

[2] Innovative therapies are costly, however, their benefits offset their expensive nature

[3] Regulatory authorities are closely monitoring emerging technologies and are regulating the process of manufacturing and marketing of drug-device combinations

[4] Indian pharma majors must partner with smaller research organisations to develop new chemical entities. NCEs offer significant growth potential for India Pharma Inc

[5] India Pharma Inc. must prioritise innovations and solutions that are critical for the Indian populace